A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

By afschroeder • June 10, 2026

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams C, Schweitzer C, Adhikary S, Jung AS, Klebanoff CA. A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial). Front Oncol. 2026 May 21;16:1809354. doi: 10.3389/fonc.2026.1809354. PMID: 42266673; PMCID: PMC13244869.

Tags: adoptive cell therapy (ACT), cell surface receptor drug targets, clinical trial results, Hematology/Oncology, immunotherapy, Publications, T-cell receptor (TCR)

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm

Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That[...]

PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma

Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.[...]

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases

Juarez Casillas JE, Nezafat M, Benitez CM, Rzechowski K, Kane N, Sjöstrand K, Anand A, Sonni I, Berenji GR, Duriseti S, Rettig MB, Nickols NG.[...]